Colorectal Cancer Treatments and Studies

Trial reports 40% complete response with added drugs in high-risk rectal cancer

Researchers studied 96 people with high-risk, locally advanced rectal cancer in a single-center phase II clinical trial. The treatment combined chemotherapy, short-course radiation, and a targeted drug selected for each study cohort. Overall, 40% had a complete response, but the study did not establish how this approach compares with other treatments.